Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968558 | 0.85 | LMNA (0.56) | MAPTSMN1; SMN2LMNAKMT2ATSHR | |
| SCHEMBL25226689 | 0.81 | KDM4E (0.60) | MAPTSMN1; SMN2LMNAKMT2ATSHR | |
| SCHEMBL30219738 | 0.81 | KDM4E (0.60) | MAPTSMN1; SMN2LMNAKMT2ATSHR | |
| SCHEMBL19420173 | 0.80 | MAPT (0.58) | MAPTSMN1; SMN2LMNAKMT2ATSHR | |
| SCHEMBL1007657 | 0.80 | LMNA (0.56) | MAPTSMN1; SMN2LMNAKMT2ATSHR | |
| SCHEMBL963619 | 0.80 | LMNA (0.53) | MAPTSMN1; SMN2LMNAKMT2ATSHR | |
| SCHEMBL20067942 | 0.79 | SIRT2 (0.65) | MAPTSMN1; SMN2LMNAKMT2ATSHR | |
| SCHEMBL8788041 | 0.78 | ALDH1A1 (0.67) | MAPTSMN1; SMN2LMNAKMT2ATSHR | |
| SCHEMBL10327053 | 0.77 | MAPT (0.55) | MAPTSMN1; SMN2LMNAKMT2ATSHR | |
| SCHEMBL12947374 | 0.77 | MAPT (0.52) | MAPTSMN1; SMN2LMNAKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | MAPT 1762/4885SMN1; SMN2 595/4885LMNA 886/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | MAPT 1460/4885SMN1; SMN2 839/4885LMNA 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.